Bulgaria
· Delayed Price · Currency is BGN THQM Statistics
Total Valuation
Tchaikapharma High Quality Medicines AD has a market cap or net worth of BGN 1.60 billion. The enterprise value is 1.61 billion.
| Market Cap | 1.60B |
| Enterprise Value | 1.61B |
Important Dates
The last earnings date was Thursday, August 29, 2024.
| Earnings Date | Aug 29, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Tchaikapharma High Quality Medicines AD has 91.80 million shares outstanding.
| Shares Outstanding | 91.80M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 81.10% |
| Owned by Institutions (%) | n/a |
| Float | 11.25M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 31.28 |
| PB Ratio | 14.33 |
| P/FCF Ratio | 1,483.12 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 836.17 |
| EV / Sales | 32.55 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 1,492.99 |
Financial Position
The company has a current ratio of 5.60, with a Debt / Equity ratio of 9.97.
| Current Ratio | 5.60 |
| Quick Ratio | 4.31 |
| Debt / Equity | 9.97 |
| Debt / EBITDA | 2.23 |
| Debt / FCF | 9.98 |
| Interest Coverage | 4.41 |
Financial Efficiency
Return on equity (ROE) is 1.80% and return on invested capital (ROIC) is 1.41%.
| Return on Equity (ROE) | 1.80% |
| Return on Assets (ROA) | 1.35% |
| Return on Capital (ROIC) | 1.41% |
| Revenue Per Employee | 245,741 |
| Profits Per Employee | 9,567 |
| Employee Count | 191 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 0.44 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +1.75% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +1.75% |
| 50-Day Moving Average | 17.26 |
| 200-Day Moving Average | 16.21 |
| Relative Strength Index (RSI) | 54.40 |
| Average Volume (20 Days) | 76 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Tchaikapharma High Quality Medicines AD had revenue of BGN 49.39 million and earned 1.92 million in profits. Earnings per share was 0.02.
| Revenue | 49.39M |
| Gross Profit | 43.50M |
| Operating Income | 2.67M |
| Pretax Income | 2.44M |
| Net Income | 1.92M |
| EBITDA | 3.98M |
| EBIT | 2.67M |
| Earnings Per Share (EPS) | 0.02 |
Balance Sheet
The company has 115,000 in cash and 10.75 million in debt, giving a net cash position of -10.63 million or -0.12 per share.
| Cash & Cash Equivalents | 115,000 |
| Total Debt | 10.75M |
| Net Cash | -10.63M |
| Net Cash Per Share | -0.12 |
| Equity (Book Value) | 107.81M |
| Book Value Per Share | 1.21 |
| Working Capital | 66.93M |
Cash Flow
In the last 12 months, operating cash flow was 3.04 million and capital expenditures -1.97 million, giving a free cash flow of 1.08 million.
| Operating Cash Flow | 3.04M |
| Capital Expenditures | -1.97M |
| Free Cash Flow | 1.08M |
| FCF Per Share | 0.01 |
Margins
Gross margin is 88.06%, with operating and profit margins of 5.40% and 3.89%.
| Gross Margin | 88.06% |
| Operating Margin | 5.40% |
| Pretax Margin | 4.94% |
| Profit Margin | 3.89% |
| EBITDA Margin | 8.06% |
| EBIT Margin | 5.40% |
| FCF Margin | 2.18% |
Dividends & Yields
Tchaikapharma High Quality Medicines AD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 0.12% |
| FCF Yield | 0.07% |
Stock Splits
The last stock split was on July 3, 2023. It was a forward split with a ratio of 1.0508876.
| Last Split Date | Jul 3, 2023 |
| Split Type | Forward |
| Split Ratio | 1.0508876 |
Scores
Tchaikapharma High Quality Medicines AD has an Altman Z-Score of 56.61.
| Altman Z-Score | 56.61 |
| Piotroski F-Score | n/a |